Recurrent Endometrial Carcinoma Completed Phase 2 Trials for DB00112 (Bevacizumab)

IndicationStatusPhase
DBCOND0028796 (Recurrent Endometrial Carcinoma)Completed2
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT00301964Bevacizumab in Treating Patients With Recurrent or Persistent Endometrial CancerTreatment